Biofrontera enters into a license and supply agreement with Galenica AB for the marketing of Ameluz® in Scandinavia
December 07, 2020 09:10 ET
|
Biofrontera AG
Leverkusen, Germany, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Biofrontera Pharma GmbH, a wholly owned subsidiary of Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), and Galenica AB, Malmö,...